Video Center


The OBR Video Center Features educational videos covering a wide range of oncology specific topics.

Mazyar Shadman, MD, on patients with B-cell malignancies who are intolerant to 1st line ibrutinib

Dr. Shadman, Physician, Seattle Cancer Care Alliance, Associate Professor, Division of Medical Oncology, UW School of Medicine, considers how often patients with relapsed/refractory B-cell malignancies are intolerant of first-line therapy with ibrutinib

Tags: ASH Conference Coverage

Published: 15 December 2020

Recent Videos: ASH Conference Coverage

video

Radhakrishnan Ramchandren, MD, provides perspective on the safety & efficacy of brentuximab vedotin

Dr. Ramchandren, Chief, Division of Hematology/Oncology, University of Tennessee Medical Center, provides perspective on the safety and efficacy of brentuximab ...

video

Radhakrishnan Ramchandren, MD, offers opinion on the ECHELON-2 trial as presented at ASH 2020

Dr. Ramchandren, Chief, Division of Hematology/Oncology, University of Tennessee Medical Center, discusses the five-year follow-up of the ECHELON-2 study investigating ...

video

Radhakrishnan Ramchandren, MD, elaborates on the five-year follow-up data from ECHELON-1

Dr. Ramchandren, Chief, Division of Hematology/Oncology, University of Tennessee Medical Center, shares details from the five-year follow-up of the ECHELON-1 ...

video

Leslie Popplewell, MD, FACP, on the challenges of delivering CAR T-cell therapy to lymphoma patients

Dr. Popplewell, Associate Clinical Professor of Hematology & Hematopoietic Cell Transplantation, Hematologist/Oncologist, City of Hope, considers the biggest challenges in ...

video

Leslie Popplewell, MD, FACP, on the management of adverse events associated with CAR T-cell therapy

Dr. Popplewell, Associate Clinical Professor of Hematology & Hematopoietic Cell Transplantation, Hematologist/Oncologist, City of Hope, regarding the management of adverse ...

video

Leslie Popplewell, MD, FACP, describes how engineered toxin bodies work as an anti-cancer treatment

Dr. Popplewell, Associate Clinical Professor of Hematology & Hematopoietic Cell Transplantation, Hematologist/Oncologist, City of Hope, describes how engineered toxin bodies ...

video

Leslie Popplewell, MD, FACP, on the future of CAR T-cell therapies in follicular lymphoma

Dr. Popplewell, Associate Clinical Professor of Hematology & Hematopoietic Cell Transplantation, Hematologist/Oncologist, City of Hope, speculates on the future of ...

video

Leslie Popplewell, MD, FACP, discusses the latest treatment trends in follicular lymphoma

Dr. Popplewell, Associate Clinical Professor of Hematology & Hematopoietic Cell Transplantation, Hematologist/Oncologist, City of Hope, shares perspective on the latest ...

video

Frederick Locke, MD, shares thoughts on the evolution of bispecific antibodies

Dr. Locke, Program Co-Leader, Immunology, Department of Blood and Marrow Transplant & Cellular Immunotherapy, Moffitt Cancer Center, shares thoughts on ...

video

Frederick Locke, MD, speculates on the future of CAR T-cell therapies

Dr. Locke, Program Co-Leader, Immunology, Department of Blood and Marrow Transplant & Cellular Immunotherapy, Moffitt Cancer Center, offers opinion on ...

Related Videos

video-image

Radhakrishnan Ramchandren, MD, provides perspective on the safety & efficacy of brentuximab vedotin

video-image

Radhakrishnan Ramchandren, MD, offers opinion on the ECHELON-2 trial as presented at ASH 2020

video-image

Radhakrishnan Ramchandren, MD, elaborates on the five-year follow-up data from ECHELON-1

video-image

Leslie Popplewell, MD, FACP, on the challenges of delivering CAR T-cell therapy to lymphoma patients

video-image

Leslie Popplewell, MD, FACP, on the management of adverse events associated with CAR T-cell therapy

video-image

Leslie Popplewell, MD, FACP, describes how engineered toxin bodies work as an anti-cancer treatment

video-image

Leslie Popplewell, MD, FACP, on the future of CAR T-cell therapies in follicular lymphoma

video-image

Leslie Popplewell, MD, FACP, discusses the latest treatment trends in follicular lymphoma

video-image

Frederick Locke, MD, shares thoughts on the evolution of bispecific antibodies

video-image

Frederick Locke, MD, speculates on the future of CAR T-cell therapies

video-image

David Sallman, MD, offers opinion on the most exciting clinical data in AML coming out of ASH 2020

video-image

Frederick Locke, MD, discusses details from the ZUMA-9 clinical study presented at ASH 2020

video-image

David Sallman, MD, offers details regarding the clinical investigation of CYAD-01

video-image

Frederick Locke, MD, offers impressions of the ZUMA-2 study presented at ASH 2020

video-image

Mazyar Shadman, MD, on the investigation of 3rd-generation CAR T-cell therapies targeting CD20

video-image

Frederick Locke, MD, summarizes outcomes from the ZUMA-1 clinical trial presented at ASH 2020

video-image

David Sallman, MD, on what the IDH2 mutation reveals about the prognosis in acute myeloid leukemia

video-image

Mazyar Shadman, MD, on the efficacy & tolerability of zanubrutinib in B-cell malignancies

video-image

David Sallman, MD, elaborates on the first-in-class anti-CD47 antibody magrolimab

video-image

Chaitra Ujjani, MD, speculates on next steps in the investigation of ibrutinib + venetoclax

video-image

Chaitra Ujjani, MD, regarding the evolving treatment landscape of follicular lymphoma

video-image

Chaitra Ujjani, MD, elaborates on the impact of new therapies in follicular lymphoma

video-image

Chaitra Ujjani, MD, considers the efficacy of ibrutinib + venetoclax in relapsed/refractory FL

video-image

Chaitra Ujjani, MD, regarding the investigation of CLL patients hospitalized with COVID-19

video-image

Lori Leslie, MD, on real-world outcomes in CLL patients receiving ibrutinib or chemoimmunotherapy

video-image

Lori Leslie, MD, discusses the Phase II Global Unity-NHL trial from ASH 2020

video-image

Lori Leslie, MD, considers whether ibrutinib + venetoclax is effective in the management of FL

video-image

Michael Savona, MD, regarding the ASCEMBL study presented at ASH 2020

video-image

David Siegel, MD, PhD, shares details from the APOLLO & CANDOR trial updates presented at ASH '20

video-image

Jennifer Brown, MD, PhD, provides perspective on the side-effect profiles of next-gen BTK inhibitors

video-image

David Siegel, MD, PhD, regarding the early test results of CC-220 presented at ASH 2020

video-image

Jennifer Brown, MD, PhD, on the addition of zanubrutinib to the NCCN Guidelines for CLL

video-image

David Siegel, MD, PhD, elaborates on outcomes from the KarMMa trial

video-image

Jennifer Brown, MD, PhD, offers opinion on how zanubrutinib fits into the CLL treatment landscape

video-image

David Siegel, MD, PhD, regarding bispecific antibodies in the management of relapsed/refractory MM

video-image

Jennifer Brown, MD, PhD, shares outcomes of Arm C of the SEQUOIA trial from ASH 2020

video-image

David Siegel, MD, PhD, summarizes outcomes from the Phase I CRB-402 study presented at ASH 2020

video-image

Jennifer Brown, MD, PhD, considers the unmet needs in patients with CLL or SLL with del(17p)

video-image

Lindsey Roeker, MD, on examining the experience of CLL patients hospitalized with COVID-19

video-image

Anthony Mato, MD, MSCE, examines different treatment approaches to BTK inhibitor intolerance

video-image

Melissa Alsina, MD, considers the role of anti-BCMA CAR-T cell therapy

video-image

Anthony Mato, MD, MSCE, elaborates on outcomes from the BRUIN trial presented at ASH 2020

video-image

Melissa Alsina, MD, shares the long-term follow-up outcomes of the Phase I CRB-402 study

video-image

Anthony Mato, MD, MSCE, shares some of the key findings on the InformCLL Registry from ASH 2020

video-image

Melissa Alsina, MD, offers opinion on anti-BCMA CAR-T cell therapy

video-image

Anthony Mato, MD, MSCE, tells us about the InformCLL Registry

video-image

Julio Chavez, MD, MS, provides perspective on exciting data in NHL coming out of ASH 2020

video-image

Julio Chavez, MD, MS, offers opinion on the significance of BCL10 mutations

video-image

Julio Chavez, MD, MS, considers the most exciting clinical studies of axi-cel in lymphoma

video-image

Julio Chavez, MD, MS, shares outcomes from the ZUMA-5 study presented at ASH 2020

video-image

Othman Al-Sawaf, MD, discusses outcomes from the 4-year follow-up of the CLL14 from ASH '20

video-image

Julio Chavez, MD, MS, discusses the unique mechanism of action of axicabtagene ciloleucel

video-image

Othman Al-Sawaf, MD, on the role of MRD in the management of CLL as a result of data from ASH 2020

video-image

Julio Chavez, MD, MS, regarding the typical treatment algorithms for relapsed/refractory iNHL

video-image

Othman Al-Sawaf, MD, on potential safety concerns associated with venetoclax combinations

video-image

Yi Lin, MD, PhD, shares impressions of the APOLLO study in relapsed/refractory MM from ASH 2020

video-image

Othman Al-Sawaf, MD, regarding the standard of care for first-line treatment of newly diagnosed CLL

video-image

Yi Lin, MD, PhD, on how anti-BCMA CAR-T cell therapy fits into the treatment of RRMM

video-image

Sattva Neelapu, MD, shares highlights in the development of CAR T-cell therapies in lymphoma

video-image

Yi Lin, MD, PhD, offers opinion on anti-BCMA CAR-T cell therapy

video-image

Sattva Neelapu, MD, elaborates on long-term results from the ZUMA-1 trial

video-image

Peter Voorhees, MD, offers opinion on the role of daratumumab as more trial data emerges

video-image

Sattva Neelapu, MD, discusses advancements in the management of CAR T-cell therapy AEs

video-image

Yi Lin, MD, PhD, discusses the unique mechanism of action of ide-cel

video-image

Sattva Neelapu, MD, speculates on the future of first-line CAR T-cell therapy in lymphoma

video-image

Peter Voorhees, MD, on progress with BCMA-targeted therapies and the challenge of relapse

video-image

Sattva Neelapu, MD, discusses details of the ZUMA-12 trial presented at ASH 2020

video-image

Michael Jain, MD, PhD, provides an update on the progress of the ZUMA-11 trial

video-image

Michael Jain, MD, PhD, on what we're learning about 'out of specification' CAR T-cell products

video-image

Michael Jain, MD, PhD, speculates on exciting studies of immunotherapy in lymphoma

video-image

Michael Jain, MD, PhD, discusses the management of CAR T-cell therapy adverse events

video-image

Michael Jain, MD, PhD, on immunotherapy treatment trends in the management of aggressive lymphomas

video-image

Michael Savona, MD, considers the practice-changing potential of the ASCERTAIN study

video-image

Stephen Ansell, MD, PhD, elaborates on treatment considerations in Waldenstrom macroglobulinemia

video-image

Michael Savona, MD, discusses outcomes from the ASCERTAIN trial presented at ASH 2020

video-image

Peter Voorhees, MD, regarding current controversies in the treatment of multiple myeloma

video-image

Michael Savona, MD, elaborates on the role of cytidine deaminase (CDA)

video-image

Stephen Ansell, MD, PhD, elaborates on bridging therapy for lymphoma patients

video-image

Peter Voorhees, MD, discusses some of the current approaches to dealing with daratumumab resistance

video-image

Stephen Ansell, MD, PhD, speculates on promising new treatment combinations in follicular lymphoma

video-image

Peter Voorhees, MD, regarding the treatment landscape in newly diagnosed & relapsed/refractory MM

video-image

Stephen Ansell, MD, PhD, on options for lymphoma patients who are refractory to CAR T-cell treatment

video-image

Stephen Ansell, MD, PhD, describes the landscape of immunotherapy approaches in lymphoma

video-image

Thomas Martin, MD, speculates on the future of the IKEMA study in relapsed multiple myeloma

video-image

Bhavana Bhatnagar, DO, on the design of clinical trials and the representation of minority patients

video-image

Bhavana Bhatnagar, DO, shares key takeaways for clinicians regarding racial disparities in AML

video-image

Thomas Martin, MD, shares thoughts on minimal residual disease as an indicator of response in MM

video-image

Bhavana Bhatnagar, DO, regarding data on racial disparities in the treatment of AML from ASH 2020

video-image

Thomas Martin, MD, talks safety concerns regarding isatuximab plus carfilzomib and dexamethasone

video-image

Bhavana Bhatnagar, DO, on the significance of examining racial disparities in the treatment of AML

video-image

Thomas Martin, MD, considers the significance of the IKEMA study

video-image

Bhavana Bhatnagar, DO, on unexpected findings from a study of racial disparities in treatment of AML

video-image

Thomas Martin, MD, discusses outcomes from the Phase III IKEMA study in relapsed MM from ASH 2020